Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register account icon
S&P 500
7,580.06
(
0.22%
)
US TECH 100
29,608.40
(
0.26%
)
Dow Jones
51,032.46
(
0.72%
)
Brent Oil
93.73
(
2.59%
)
Bitcoin
72,810.00
(
-1.01%
)
News Focus
News Focus
Post# of 966
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 123040
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: None

Monday, 03/27/2023 5:52:42 PM

Monday, March 27, 2023 5:52:42 PM

Post# of 966
Keytruda shows statsig-superior PFS as addend to chemo in Stage-III/IV (or recurrent) endometrial cancer:

https://www.businesswire.com/news/home/20230327005147/en

The HR for PFS was 0.54 in the pMMR subgroup and 0.30(!) in the dMMR subgroup.

The OS results are not disclosed in the PR, so they are presumably not mature. (OS was a secondary endpoint.)

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent MRK News
More MRK News